No description available.

Personen unterscheiden sich in dem, wie sie sich im Allgemeinen fühlen. Das Ziel dieser Dissertation ist es, die Prozesse, die diesen Personenunterschieden zugrunde liegen, zu verstehen. Es wurden insbesondere die affektiven Prozesse affektive Reaktivität und Emotionsregulation untersucht. In drei Studien wurden die folgenden Forschungsfragen untersucht: (1) Haben Personen mit höherem subjektiven Wohlbefinden einen stärkeren Anstieg in positivem Affekt, wenn sie auf positive Stimuli im Labor reagieren oder ihre positiven Emotionen hochregulieren? (2) Welches sind die neuronalen Korrelate, die diesen kurzfristigen Veränderungen in positivem Affekt zugrunde liegen, insbesondere während der Hochregulation positiver Emotionen? (3) Hängt ein höheres subjektives Wohlbefinden mit einer stärkeren oder geringeren Reaktion auf positive Ereignisse im Alltag zusammen? Die Befunde haben gezeigt, dass ein stärkerer Anstieg in positivem Affekt (durch eine stärkere Reaktion auf positive Ereignisse oder durch das Hochregulieren positiver Emotionen) nicht mit einem höheren subjektiven Wohlbefinden zusammenhängt. Stattdessen hatten Personen mit einem höheren subjektiven Wohlbefinden eine geringere Reaktivität auf positive Ereignisse im Alltag. Auf der neuronalen Ebene spiegelten sich die Veränderungen in positivem Affekt durch eine verstärkte neuronale Aktivierung in emotionsbezogenen Regionen (insbesondere des ventralen Striatums) wieder, sowie durch eine Deaktivierung in einem fronto-parietalen Kontrollnetzwerk. Ein Zusammenhang von neuronaler Aktivierung und Veränderungen in positivem Affekt im Alltag wurde nicht gefunden. Die Arbeit dieser Dissertation zeigt, dass nicht besonders intensives positives Erleben, sondern eher weniger Schwankungen in momentanen positiven Affekt wichtig für das Wohlbefinden sind. Darüber hinaus zeigt diese Dissertation die Wichtigkeit auf verschiedene Analyseebenen und Untersuchungsmethoden in die Erforschung von affektivem Erleben zu integrieren. / This dissertation investigates the affective processes – affective reactivity and emotion regulation – underlying short-term changes in positive affective experiences and their relation to interindividual differences in subjective well-being. The main research objectives that were addressed in the empirical studies of this dissertation concerned (1) whether stronger increases in positive affect when reacting to and when up-regulating in response to positive stimuli in the laboratory relate to higher subjective well-being, (2) which brain regions underlie changes in positive affective experiences, particularly during the up-regulation of positive emotions, and (3) whether enhanced or reduced affective reactivity to positive events in daily life relates to higher subjective well-being. Findings showed that greater increases in positive affect were not related to higher subjective well-being, both when investigated in the laboratory and in daily life. Instead, people with higher levels of subjective well-being showed reduced affective reactions to positive events in daily life, pointing to the importance of a relative greater emotional stability. At the neural level, changes in positive affective experiences were mirrored by increased activations in emotion-related (e.g., ventral striatum) regions as well as deactivation in a fronto-parietal control network. These neural activations were not related to changes in positive affective experiences in daily life. The work in this dissertation indicates that not the experience of particularly intense positive affective states, but rather less fluctuation in momentary positive affective experiences seems to be essential to the overall composition of subjective well-being. The present dissertation further emphasizes the need to integrate different methods in the study of emotion. Concluding, this dissertation advances our understanding of the processes underlying subjective well-being.

Background: Patients suffering from panic disorder and agoraphobia are significantly impaired in daily life due to anxiety about getting into a situation due to apprehension about experiencing a panic attack, especially if escape may be difficult. Dysfunctional beliefs and behavior can be changed with cognitive behavioral therapy; however, the neurobiological effects of such an intervention on the anticipation and observation of agoraphobia-specific stimuli are unknown. Methods: We compared changes in neural activation by measuring the blood oxygen level-dependent signal of 51 patients and 51 healthy controls between scans before and those after treatment (group by time interaction) during anticipation and observation of agoraphobia-specific compared to neutral pictures using 3-T fMRI. Results: A significant group by time interaction was observed in the ventral striatum during anticipation and in the right amygdala during observation of agoraphobia-specific pictures; the patients displayed a decrease in ventral striatal activation during anticipation from pre- to posttreatment scans, which correlated with clinical improvement measured with the Mobility Inventory. During observation, the patients displayed decreased activation in the amygdala. These activational changes were not observed in the matched healthy controls. Conclusions: For the first time, neural effects of cognitive behavioral therapy were shown in patients suffering from panic disorder and agoraphobia using disorderspecific stimuli. The decrease in activation in the ventral striatum indicates that cognitive behavioral therapy modifies anticipatory anxiety and may ameliorate abnormally heightened salience attribution to expected threatening stimuli. The decreased amygdala activation in response to agoraphobia-specific stimuli indicates that cognitive behavioral therapy can alter the basal processing of agoraphobia-specific stimuli in a core region of the fear network.

A esquizofrenia é uma desordem altamente incapacitante que atinge cerca de 1% da população, envolvendo desequilíbrio da neurotransmissão dopaminérgica e uma hipofunção glutamatérgica. Portadores dessa doença apresentam deficiência do processamento de informações caracterizada por prejuízo no teste de inibição pré-pulso (prepulse inhibition - PPI). Essa condição pode ser reproduzida em modelos experimentais, pelo tratamento com psicoestimulantes, como a anfetamina (ANF) e atenuado/revertido pelo tratamento com antipsicóticos. O canabidiol (CBD) é o principal componente não psicotomimético da Cannabis sativa. Estudos clínicos e pré-clínicos sugerem que o CBD apresenta perfil antipsicótico, com baixa indução de efeitos adversos. Contudo, até o momento poucos estudos foram realizados com o objetivo de investigar os mecanismos farmacológicos e/ou moleculares envolvidos nesse perfil. Os prováveis mecanismos envolvidos com as propriedades antipsicóticas do CBD parecem envolver a ativação de receptores TRPV1 e o aumento da sinalização do endocanabinoide anandamida. No presente estudo, demonstramos que os receptores TRPV1 e o aumento da disponibilidade de anandamida parecem participar do perfil antipsicótico do CBD. Nessas investigações, não observamos participação dos receptores 5-HT1A. A microinjeção de CBD no córtex pré-frontal (CPF), estrutura envolvida com a fisiopatologia da esquizofrenia e um provável sítio para ação de antipsicóticos, não atenuou o prejuízo induzido por ANF no PPI. Recentemente, mecanismos epigenéticos, como a metilação do DNA, têm sido associados à fisiopatologia da esquizofrenia. Nesse sentido, avaliamos o envolvimento da metilação do DNA em estruturas envolvidas com a neurobiologia da esquizofrenia regulada por CBD, sobre as respostas comportamentais induzidas por drogas psicotomiméticas. Verificamos que a ANF causa um aumento da metilação global no estriado ventral, efeito bloqueado pelo pré-tratamento com CBD e de forma semelhante com o antipsicótico clozapina (CLZ). Não observamos alterações na metilação global no CPF. O tratamento com MK-801 não alterou a metilação global nas duas estruturas anteriormente citadas. Protocolo experimental semelhante foi utilizado em mais duas abordagens: (i) a expressão do fator neurotrófico do cérebro (BDNF), relacionado com a manutenção, crescimento e diferenciação dos neurônios está aumentada no hipocampo dos animais tratados com a associação CBD e ANF, padrão semelhante foi observado com a associação CLZ e ANF. (ii) a expressão de fosfo-histona acetilada, um marcador que indica alterações na cromatina, intimamente ligada com as alterações da expressão gênica está aumentada no núcleo acumbens e CPF dos animais tratados com a associação CBD e ANF. Os dados aqui apresentados sugerem que os receptores TRPV1 e o endocanabinoide anandamida parecem estar envolvidos com o perfil antipsicótico do CBD. Pela primeira vez foi demonstrado que tanto o pré-tratamento com CBD ou CLZ podem alterar o aumento da metilação global de DNA induzido por ANF. Além disso, a expressão de BDNF no hipocampo e a expressão de fosfo-histona acetilada podem ser outros mecanismos que merecem atenção em relação ao perfil antipsicótico do CBD. / Schizophrenia is a highly disabling disorder that affects about 1% of the population and involves impaired dopaminergic neurotransmission and glutamatergic hypofunction. Patients with this disorder have a deficiency in information processing characterized by disruption in the prepulse inhibition (PPI) test. This condition can be reproduced in experimental models by treatment with psychostimulants such as amphetamine and attenuated / reversed by treatment with antipsychotics. Cannabidiol (CBD) is the main non-psychotomimetic component of Cannabis sativa. Clinical and preclinical studies suggest that CBD has an antipsychotic profile, with low induction of adverse effects. However, to date, few studies have been carried out to investigate the pharmacological and / or molecular mechanisms involved in this outcome. The likely mechanisms involved with the antipsychotic properties of CBD appear to involve activation of TRPV1 receptors and increased endocannabinoid anandamide signaling. In the present study, we demonstrated that TRPV1 receptors and the increased availability of anandamide appear to participate in the CBD antipsychotic profile. In these investigations, we did not observe participation of 5-HT1A receptors. Microinjection of CBD in the prefrontal cortex, structure involved in the pathophysiology of schizophrenia and a probable site of antipsychotic action, did not attenuate the amphetamine-induced disruption in PPI. Recently, epigenetic mechanisms, such as DNA methylation, have been associated with the pathophysiology of schizophrenia. In this sense, we also evaluated the involvement of DNA methylation in structures involved with the neurobiology of CBD-regulated schizophrenia on behavioral responses induced by psychotomimetic drugs. We found that amphetamine causes increased global methylation in the ventral striatum, an effect blocked by pre-treatment with CBD and similarly with the antipsychotic clozapine. We did not observe changes in the global methylation in prefrontal cortex. Treatment with MK-801 did not alter the global methylation in the two aforementioned structures. Similar experimental protocol was used in two other approaches: (i) brain neurotrophic factor (BDNF) expression, related to the maintenance, growth and differentiation of neurons is increased in the hippocampus of animals treated with CBD and amphetamine; a similar pattern was observed with the association clozapine and amphetamine. (ii) the expression of acetylated phospho-histone, a marker indicating changes in chromatin, closely linked to changes in gene expression is increased in the nucleus acumbens and CPF in animals treated with the CBD and amphetamine combination. The data presented here suggest TRPV1 receptors and the endocannabinoid anandamide seem to be involved with the antipsychotic profile of CBD. For the first time it has been shown that both pre-treatment with CBD or clozapine may alter the increase in overall DNA methylation induced by amphetamine. In addition, the expression of BDNF in the hippocampus and the expression of acetylated phospho-histone may be different mechanisms that deserve attention in relation to the antipsychotic profile of CBD.

No description available.

Background: Panic disorder with agoraphobia is characterized by panic attacks and anxiety in situations where escape might be difficult. However, neuroimaging studies specifically focusing on agoraphobia are rare. Here we used functional magnetic resonance imaging (fMRI) with disorder-specific stimuli to investigate the neural substrates of agoraphobia. Method. We compared the neural activations of 72 patients suffering from panic disorder with agoraphobia with 72 matched healthy control subjects in a 3-T fMRI study. To isolate agoraphobia-specific alterations we tested the effects of the anticipation and perception of an agoraphobia-specific stimulus set. During fMRI, 48 agoraphobia-specific and 48 neutral pictures were randomly presented with and without anticipatory stimulus indicating the content of the subsequent pictures (Westphal paradigm). Results: During the anticipation of agoraphobia-specific pictures, stronger activations were found in the bilateral ventral striatum and left insula in patients compared with controls. There were no group differences during the perception phase of agoraphobia-specific pictures. Conclusions: This study revealed stronger region-specific activations in patients suffering from panic disorder with agoraphobia in anticipation of agoraphobia-specific stimuli. Patients seem to process these stimuli more intensively based on individual salience. Hyperactivation of the ventral striatum and insula when anticipating agoraphobiaspecific situations might be a central neurofunctional correlate of agoraphobia. Knowledge about the neural correlates of anticipatory and perceptual processes regarding agoraphobic situations will help to optimize and evaluate treatments, such as exposure therapy, in patients with panic disorder and agoraphobia.

Avoiding loss is a crucial, adaptive guide to human behavior. While previous developmental research has primarily focused on gaining rewards, less attention has been paid to loss processing and its avoidance. In daily life, it is often unknown how likely an action will result in a loss, making the role of uncertainty in loss processing particularly important. By using functional magnetic resonance imaging, we investigated the influence of varying outcome probabilities (12%, 34%, and 67%) on brain regions implicated in loss processing (ventral striatum (VS), anterior insula (AI)) by comparing 28 adolescents (10–18 years) and 24 adults (22–32 years) during the anticipation of potential monetary loss. Overall, results revealed slower RTs in adolescents compared to adults with both groups being faster in the experimental (monetary condition) vs. control trials (verbal condition). Fastest RTs were observed for the 67% outcome probability in both age groups. An age group × outcome probability interaction effect revealed the greatest differences between the groups for the 12% vs. the 67% outcome probability. Neurally, both age groups demonstrated a higher percent signal change in the VS and AI during the anticipation of potential monetary loss versus the verbal condition. However, adults demonstrated an even greater activation of VS and AI than adolescents during the anticipation of potential monetary loss, but not during the verbal condition. This may indicate that adolescents differ from adults regarding their experience of avoiding losing monetary rewards.

Pathologisches Glücksspiel (PG) ist eine psychiatrische Erkrankung, die gerade erst im DSM-5 der gleichen Kategorie wie substanzgebundene Suchterkrankungen zugeordnet wurde. Bildgebungsstudien zu Substanzabhängigkeit beobachteten funktionelle und strukturelle Veränderungen im präfrontalen Kortex (PFC) und mesolimbischen Belohnungssystem (d.h. Striatum). Für PG wurden ähnliche Veränderungen berichtet; jedoch gibt es kaum Studien, die sich mit verschiedenen Aspekten funktioneller und struktureller Korrelate in diesen Regionen beschäftigen. Diese Arbeit untersuchte PG Patienten, alkoholabhängige (AD) Patienten und Kontrollpersonen (HC) mit Magnetresonanztomografie. In Analyse I wurden funktionelle Gehirndaten während der Belohnungsaufgabe zwischen den drei Gruppen verglichen. In Analyse II wurde das Volumen grauer Substanz mit voxelbasierter Morphometrie und in Analyse III die intrinsische Gehirnaktivität mit einer seedbasierten funktionellen Konnektivitätsanalyse von PG Patienten und HC ausgewertet. Die Analysen ergaben veränderte Aktivierungen in frontostriatalen Arealen während der Verarbeitung von Verlustvermeidung für PG Patienten im Vergleich zu HC. PG Patienten unterschieden sich dabei in ihrer Aktivierung von AD Patienten während der Antizipation von Geldverlust. Weiterhin zeigten PG Patienten erhöhte Volumina grauer Substanz und eine erhöhte funktionelle Konnektivität in frontostriatalen Arealen im Vergleich zu HC. Die Ergebnisse liefern weitere Hinweise für eine veränderte Belohnungsverarbeitung in PG und betonen die Bedeutung der Verlustvermeidungsverarbeitung. Die Volumenveränderungen im und die erhöhte Konnektivität zwischen dem PFC and Belohnungssystem deuten auf eine veränderte Interaktion zwischen diesen Regionen hin. Da solche Veränderungen in kortikostriatalen Systemen Ähnlichkeiten zu denen in Substanzabhängigkeiten aufweisen, unterstützen die Ergebnisse die neue Klassifikation des PG im DSM-5. / Pathological gambling (PG) is a psychiatric disorder newly classified under the same category as substance use disorders in the DSM-5. Neuroimaging studies on substance-related addictions reported functional and structural changes in the prefrontal cortex (PFC) and the mesolimbic reward system (i.e., striatum). For PG, findings are not that extensive, but also demonstrate altered reward processing and prefrontal function. However, there is a lack of studies focusing on different aspects of functional and structural correlates within these areas in PG. This thesis investigated PG patients, alcohol dependent (AD) patients and healthy controls with magnetic resonance imaging (MRI). In analysis I, functional brain data of a reward paradigm was compared between the three groups. In analysis II, local gray matter volume of PG patients and controls was processed via voxel-based morphometry. Resting-state data of PG patients and controls was analyzed via seed-based functional connectivity in analysis III. Results revealed altered brain responses in fronto-striatal areas during loss avoidance processing in PG patients as compared to controls. Importantly, PG patients differed in their brain responses from AD patients during the prospect of monetary loss. Moreover, PG patients showed an increase in local gray matter volume and functional connectivity in frontal-striatal areas as compared to controls. Our results add further evidence for an altered reward processing in PG and underline the importance of loss avoidance processing. Moreover, our findings of volumetric alterations within and increased connectivity between PFC and reward system, suggest an altered interaction between these brain regions. Since such alterations in cortico-striatal circuits resemble those reported for substance-related addictions, our findings support the new classification of PG in the DSM-5.